Videos

The vascular neurology fellow at the University of Maryland Medical Center discussed findings that African American women had the lowest functional performance in stroke rehabilitation.

The professor of neurology at Mayo Clinic discussed the reasoning for the research he presented at AAN 2021 on social determinants and their impact on epilepsy treatment times.

Neurology News Network for the week ending April 17, 2021.

The chief of neurology at Ascension Saint Agnes discussed her team’s efforts to increase compliance in providing patient-specific stroke DCI.

Episode 9 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the Veterans Health Administration; and Douglas J. Gelb, MD, PhD, of the University of Michigan [WATCH TIME: 5 minutes]

Clinicians elaborate on key trial data revealed through the APOLLO and NEURO-TTR studies in hereditary ATTR amyloidosis.

Treatment overview of hereditary ATTR amyloidosis and considerations for using newer therapies such as patisiran or inotersen in appropriate patients.

A panel of key opinion leaders in neurology considers the importance of newborn screening for spinal muscular atrophy in order to start patients on treatment as early as possible.

Thomas Crawford, MD, discusses the classification of different phenotypes of SMA and comments on the degree to which these classifications are relevant to treatment approaches.

The neurologist from Mayo Clinic discussed his abstract at AAN 2021 comparing stroke rates in patients with cerebral amyloid antipathy given treatment with aspirin.

The director and founder of the Sleep Centers of Middle Tennessee discussed strategies to achieve long term adherence to cPAP from patients with obstructive sleep apnea.

The consultant in the Department of Neurology at Mayo Clinic discussed the mechanisms of action researchers should key in on for patients with Parkinson disease.

Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.

A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.

The professor of health science at the Medical University of South Carolina detailed the limits of what can be achieved with behavioral interventions for the symptoms of dementia.

The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about further research his lab is conducting into MS mechanisms.

Key opinion leaders in neurology discuss the safety and efficacy of apomorphine hydrochloride and provide insights into the advantages and disadvantages of its subcutaneous formulation.

Laxman Bahroo, DO and Mindy K. Bixby, DO define OFF episodes in Parkinson’s Disease and discuss how they are often unpredictable and variable in their severity.

Jill Dehlin, RN, a patient with migraine, talks about her experience receiving a subcutaneous injectable CGRP inhibitor, and neurologist Jessica Ailani, MD, explains what she counsels her patients on when prescribing a newer injectable treatment. 

Jessica Ailani, MD, a neurologist from MedStar Health, shares insight on best practices for dosing therapies used to treat migraine and implications for combining drugs together.

The assistant professor of neurology at Thomas Jefferson University discussed the potential and feasibility of brain implants in patients with stroke.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of progressive MS that need more attention and research.

Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.

Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.  

Expert neurologists discuss the variability of signs and symptoms as well as other factors to consider when diagnosing patients with amyotrophic lateral sclerosis (ALS).

A panel of key opinion leaders in neurology provides an overview of the prevalence of amyotrophic lateral sclerosis (ALS) and discusses potential causes and risk factors.

The postdoctoral researcher at Columbia University discussed the use of the DISCO-MS survey and its potential for future research projects.

The director and founder of the Sleep Centers of Middle Tennessee discussed the OSAinHome program that his practice has developed.

Richard describes the journey of his diagnosis with multiple sclerosis.

The professor of neurology at Johns Hopkins University, and a member of the Curing Coma Campaign’s Scientific Steering Committee spoke to the current limitations of clinical trials in coma.